In his weekly clinical update, Dr. Griffin discusses modeling poliovirus transmission and responses in New York State, FDA approves first vaccine for pregnant individuals to prevent RSV in infants, prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Cmmittee on Immunization Practices, Nirmatrelvir resistance – de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure, incidence of new-onset hypertension post–COVID-19: comparison with influenza, and post-acute sequelae of COVID-19 at 2 years.

TWiV reviews evidence that symptomatic adenovirus infection leads to thrombocytopenia, thrombosis, and production of anti-platelet factor 4 antibodies similar to the rare disorder seen after immunization with adenoviral vectored COVID-19 vaccines, and a monoclonal antibody isolated from a SARS survivor, following vaccination with a SARS-CoV-2 spike mRNA vaccine, that neutralizes a broad collection of ACE2-binding sarbecoviruses..

In his weekly clinical update, Dr. Griffin discusses Florida local transmission of dengue cases reported in Broward and Miami-Dade counties, infants admitted to US intensive care units for RSV infection during the 2022 seasonal peak, long-term risk of death and readmission after hospital admission with COVID-19 among older adults, safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with advanced chronic kidney disease and COVID-19, Fluvoxamine vs placebo for outpatients with symptomatic COVID-19, the effect of corticosteroids, antibiotics, and anticoagulants on the development of post-COVID-19 syndrome in COVID-19 hospitalized patients 6 months after discharge, long COVID and significant activity limitation among adults, incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong, and diabetes following SARS-CoV-2 infection: Incidence, persistence, and implications of COVID-19 vaccination.

TWiV dissects a study of COVID-19 vaccination which shows that the timing of initial rollout affects disease outcomes more substantially than final coverage or degree of socioeconomic disparity, and discovery of a novel cellular defense comprising a nuclease that is activated by poxvirus infection and cleaves a specific tRNA molecule to inhibit protein synthesis.

In his weekly clinical update, Dr. Griffin discusses the immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate, association between nose picking and SARS-CoV-2 incidence, a cohort study in hospital health care workers; effect of COVID-19 vaccination and booster on maternal-fetal outcomes, dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA, does monoclonal antibody treatment for COVID-19 impact short and long- term outcomes in a large generalizable population, persistent endothelial dysfunction in post-COVID-19 syndrome and its associations with symptom severity and chronic inflammation, core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts.

In his weekly clinical update, Dr. Griffin discusses predicting COVID-19 incidence using wastewater surveillance data, use of wastewater metrics to track COVID-19 in the US, wastewater-based epidemiology predicts COVID-19-induced weekly new hospital admissions in over 150 USA counties, association between duration of SARS-CoV-2 positivity and long COVID, rapid direct detection of SARS-CoV-2 aerosols in exhaled breath at the point of care, effectiveness of oral Nirmatrelvir/Ritonavir vs. intravenous three-day Remdesivir in preventing progression to severe COVID-19, NIH launching of several phase 2 long-COVID treatment trials.

TWiV notes the passing of virologist Michael BA Oldstone, a study to assess the performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 infection, and the presence of antibodies to type I interferons in ~40% of patients with West Nile virus encephalitis.

In his weekly clinical update, Dr. Griffin discusses the use of RSV vaccines in older adults: recommendations of the advisory committee on immunization practices, case report of leprosy in Central Florida, blood group A enhances SARS-CoV-2 infection, predicting COVID-19 incidence using wastewater surveillance data, a common allele of HLA associated with asymptomatic SARS-CoV-2 infection, prevalence of low-frequency, antiviral resistance variants in SARS-CoV-2 isolates in Ontario, Canada, viral resistance analyses from the Remdesivir phase 3 adaptive COVID-19 treatment trial-1, impact of Molnupiravir treatment on patient-reported COVID-19 symptoms in the phase 3 move-out trial, Molnupiravir for treatment of adults with mild or moderate COVID-19, delayed intubation associated with in-hospital mortality in patients with COVID-19 respiratory failure who fail heated and humified high flow nasal canula, relationship between azithromycin and cardiovascular outcomes in unvaccinated patients with COVID‐19 and preexisting cardiovascular disease, and the effects of COVID-19 on cognitive performance in a community-based cohort, clinical phenotypes and quality of life to define post-COVID-19 syndrome.